View Archive »
About The Cover
The cover for issue 90 of Oncotarget features Figure 4, "Docking of 2HF, DNPSG and ATP to RLIP76," by Awasthi, et al.
|
|
Table of Contents
News
|
| Targeting mesothelin in ovarian cancer |
|
https://doi.org/10.18632/oncotarget.26350
|
| 36050-36051 |
Editorial
|
| Purinergic signaling regulates mobilization of hematopoietic stem cells |
|
https://doi.org/10.18632/oncotarget.26290
|
| 36052-36054 |
|
| PHIPing along: Evolution of PHIP as a cancer biomarker and a target for therapy |
|
https://doi.org/10.18632/oncotarget.26341
|
| 36055-36056 |
Research Papers
|
| Decreased long intergenic noncoding RNA P7 predicts unfavorable prognosis and promotes tumor proliferation via the modulation of the STAT1MAPK pathway in hepatocellular carcinoma |
|
https://doi.org/10.18632/oncotarget.23282
|
| 36057-36066 |
|
| Decreased levels of regulatory B cells in patients with acute pancreatitis: association with the severity of the disease |
|
https://doi.org/10.18632/oncotarget.23911
|
| 36067-36082 |
|
| Exosomes impact survival to radiation exposure in cell line models of nervous system cancer |
|
https://doi.org/10.18632/oncotarget.26300
|
| 36083-36101 |
|
| Inhibition of breast cancer metastasis to the lungs with UBS109 |
|
https://doi.org/10.18632/oncotarget.26302
|
| 36102-36109 |
|
| A combined microfluidictranscriptomic approach to characterize the extravasation potential of cancer cells |
|
https://doi.org/10.18632/oncotarget.26306
|
| 36110-36125 |
|
| Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implantassociated anaplastic large cell lymphoma |
|
https://doi.org/10.18632/oncotarget.26308
|
| 36126-36136 |
|
| Identification of rare levels of methylated tumor DNA fragments using an optimized bias based preamplificationdigital droplet PCR OBBPAddPCR |
|
https://doi.org/10.18632/oncotarget.26315
|
| 36137-36150 |
|
| Human liver stem cellderived extracellular vesicles enhance cancer stem cell sensitivity to tyrosine kinase inhibitors through Akt/mTOR/PTEN combined modulation |
|
https://doi.org/10.18632/oncotarget.26319
|
| 36151-36165 |
|
| Differential gene expression in human tissue resident regulatory T cells from lung colon and blood |
|
https://doi.org/10.18632/oncotarget.26322
|
| 36166-36184 |
|
| Inhibition of heparanase protects against chronic kidney dysfunction following ischemia/reperfusion injury |
|
https://doi.org/10.18632/oncotarget.26324
|
| 36185-36201 |
|
| Anticancer activity of 2′hydroxyflavanone towards lung cancer |
|
https://doi.org/10.18632/oncotarget.26329
|
| 36202-36219 |
|
| The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension |
|
https://doi.org/10.18632/oncotarget.26333
|
| 36220-36237 |
|
| Monitoring BRAF and NRAS mutations with cellfree circulating tumor DNA from metastatic melanoma patients |
|
https://doi.org/10.18632/oncotarget.26343
|
| 36238-36249 |
Corrections
|
| Correction: Serine 207 phosphorylated lysyltRNA synthetase predicts diseasefree survival of nonsmallcell lung carcinoma |
|
https://doi.org/10.18632/oncotarget.26387
|
| 36250-36250 |
|
| Correction: Lung cancer susceptibility from GSTM1 deletion and air pollution with smoking status: a metaprediction of worldwide populations |
|
https://doi.org/10.18632/oncotarget.26388
|
| 36251-36251 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
